Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;41(6):1335-1343.
doi: 10.1111/liv.14871. Epub 2021 Mar 18.

Safety of fibrates in cholestatic liver diseases

Andres F Carrion  1 , Keith D Lindor  2   3 , Cynthia Levy  1
Affiliations

Safety of fibrates in cholestatic liver diseases

Andres F Carrion et al. Liver Int. 2021 Jun.

Abstract

Background and aim: Off-label use of fibrates in patients with cholestatic liver diseases results in improved biochemical parameters and pruritus; however, their safety in this population has been a concern. This study summarizes safety data for fibrates when used for treatment of cholestatic liver diseases.

Methods: A systematic review of published studies evaluating the use of fibrates for treatment of primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) was performed. Electronic databases were searched up to December 2019 for published studies evaluating treatment outcomes associated to fibrates for these 2 diseases.

Results: A total of 37 studies were identified, including 31 for PBC and 6 for PSC, with a total of 1107 unique patients treated with fibrates ± ursodeoxycholic acid (UDCA). Most studies evaluated fenofibrate and bezafibrate, and only 1 study evaluated pemafibrate. There were no studies evaluating gemfibrozil or clofibrate. The most commonly reported adverse events (AEs) were gastrointestinal and musculoskeletal. Elevations of aminotransferases and serum creatinine were reported more commonly in patients treated with UDCA plus fibrates versus UDCA monotherapy.

Conclusions: Fibrates appear to be safe and well tolerated in patients with PBC, with a low frequency of AEs. There are scarce data about the safety of these agents for treatment of PSC.

Keywords: bezafibrate; fenofibrate; fibrates; primary biliary cholangitis; primary sclerosing cholangitis.

PubMed Disclaimer

References

REFERENCES

    1. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
    1. Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology. 2015;62:635-643.
    1. Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Investig. 1995;96:741-750.
    1. El-Sisi A, Hegazy S, El-Khateeb E. Effects of three different fibrates on intrahepatic cholestasis experimentally induced in rats. PPAR Res. 2013;2013:781348.
    1. Zumoff B. Effect of clofibrate on plasma levels of alkaline phosphatase. N Engl J Med. 1977;297:669.

Publication types

MeSH terms

LinkOut - more resources